vs
HARTE HANKS INC（HHS）与RECURSION PHARMACEUTICALS, INC.（RXRX）财务数据对比。点击上方公司名可切换其他公司
HARTE HANKS INC的季度营收约是RECURSION PHARMACEUTICALS, INC.的1.1倍（$39.9M vs $35.5M），HARTE HANKS INC净利率更高（5.5% vs -304.2%，领先309.8%），RECURSION PHARMACEUTICALS, INC.同比增速更快（681.7% vs -15.4%），HARTE HANKS INC自由现金流更多（$-686.0K vs $-47.3M），过去两年RECURSION PHARMACEUTICALS, INC.的营收复合增速更高（60.5% vs -6.4%）
哈特·汉克斯是一家总部位于美国马萨诸塞州波士顿的全球营销服务企业，主营业务涵盖数据分析、营销战略规划、营销技术支持、创意服务、数字营销、客户服务、直邮服务以及物流履约等多个领域，为全球客户提供全方位的营销解决方案。
Recursion Pharmaceuticals是一家临床阶段生物技术企业，依托人工智能技术和高通量生物实验体系，开发针对罕见病、肿瘤、炎症性疾病等领域未满足医疗需求的创新疗法，核心市场覆盖北美，与全球多家生物制药企业合作推进在研管线落地。
HHS vs RXRX — 直观对比
营收规模更大
HHS
是对方的1.1倍
$35.5M
营收增速更快
RXRX
高出697.2%
-15.4%
净利率更高
HHS
高出309.8%
-304.2%
自由现金流更多
HHS
多$46.6M
$-47.3M
两年增速更快
RXRX
近两年复合增速
-6.4%
损益表 — Q4 FY2025 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $39.9M | $35.5M |
| 净利润 | $2.2M | $-108.1M |
| 毛利率 | — | 59.8% |
| 营业利润率 | -0.3% | -304.8% |
| 净利率 | 5.5% | -304.2% |
| 营收同比 | -15.4% | 681.7% |
| 净利润同比 | — | 39.6% |
| 每股收益（稀释后） | $0.30 | $-0.17 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收HHSRXRX
| Q4 25 | $39.9M | $35.5M | ||
| Q3 25 | $39.5M | $5.2M | ||
| Q2 25 | $38.6M | $19.2M | ||
| Q1 25 | $41.6M | $14.7M | ||
| Q4 24 | $47.1M | $4.5M | ||
| Q3 24 | $47.6M | $26.1M | ||
| Q2 24 | $45.0M | $14.4M | ||
| Q1 24 | $45.4M | $13.8M |
净利润HHSRXRX
| Q4 25 | $2.2M | $-108.1M | ||
| Q3 25 | $-2.3M | $-162.3M | ||
| Q2 25 | $-335.0K | $-171.9M | ||
| Q1 25 | $-392.0K | $-202.5M | ||
| Q4 24 | — | $-178.9M | ||
| Q3 24 | $142.0K | $-95.8M | ||
| Q2 24 | $-27.8M | $-97.5M | ||
| Q1 24 | $-171.0K | $-91.4M |
毛利率HHSRXRX
| Q4 25 | — | 59.8% | ||
| Q3 25 | — | -183.8% | ||
| Q2 25 | — | -4.9% | ||
| Q1 25 | — | -48.0% | ||
| Q4 24 | — | -181.4% | ||
| Q3 24 | — | 53.7% | ||
| Q2 24 | — | 36.2% | ||
| Q1 24 | — | 19.1% |
营业利润率HHSRXRX
| Q4 25 | -0.3% | -304.8% | ||
| Q3 25 | 1.3% | -3327.6% | ||
| Q2 25 | 0.1% | -916.8% | ||
| Q1 25 | -0.1% | -1297.9% | ||
| Q4 24 | -3.3% | -4042.4% | ||
| Q3 24 | 4.0% | -377.1% | ||
| Q2 24 | 3.0% | -697.4% | ||
| Q1 24 | 0.8% | -698.4% |
净利率HHSRXRX
| Q4 25 | 5.5% | -304.2% | ||
| Q3 25 | -5.8% | -3135.3% | ||
| Q2 25 | -0.9% | -894.2% | ||
| Q1 25 | -0.9% | -1373.3% | ||
| Q4 24 | — | -3935.5% | ||
| Q3 24 | 0.3% | -367.5% | ||
| Q2 24 | -61.8% | -676.6% | ||
| Q1 24 | -0.4% | -662.4% |
每股收益（稀释后）HHSRXRX
| Q4 25 | $0.30 | $-0.17 | ||
| Q3 25 | $-0.31 | $-0.36 | ||
| Q2 25 | $-0.05 | $-0.41 | ||
| Q1 25 | $-0.05 | $-0.50 | ||
| Q4 24 | $-0.31 | $-0.56 | ||
| Q3 24 | $0.02 | $-0.34 | ||
| Q2 24 | $-3.84 | $-0.40 | ||
| Q1 24 | $-0.02 | $-0.39 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $5.6M | $743.3M |
| 总债务越低越好 | — | $9.6M |
| 股东权益账面价值 | $20.5M | $1.1B |
| 总资产 | $91.8M | $1.5B |
| 负债/权益比越低杠杆越低 | — | 0.01× |
8季度趋势，按日历期对齐
现金及短期投资HHSRXRX
| Q4 25 | $5.6M | $743.3M | ||
| Q3 25 | $6.5M | $659.8M | ||
| Q2 25 | $4.8M | $525.1M | ||
| Q1 25 | $9.0M | $500.5M | ||
| Q4 24 | $9.8M | $594.4M | ||
| Q3 24 | $5.9M | $427.6M | ||
| Q2 24 | $11.0M | $474.3M | ||
| Q1 24 | $11.5M | $296.3M |
总债务HHSRXRX
| Q4 25 | — | $9.6M | ||
| Q3 25 | — | $11.9M | ||
| Q2 25 | — | $14.2M | ||
| Q1 25 | — | $16.4M | ||
| Q4 24 | — | $19.0M | ||
| Q3 24 | — | $20.5M | ||
| Q2 24 | — | $22.9M | ||
| Q1 24 | — | — |
股东权益HHSRXRX
| Q4 25 | $20.5M | $1.1B | ||
| Q3 25 | $19.9M | $1.0B | ||
| Q2 25 | $22.2M | $919.1M | ||
| Q1 25 | $21.4M | $933.9M | ||
| Q4 24 | $21.7M | $1.0B | ||
| Q3 24 | $21.0M | $524.6M | ||
| Q2 24 | $20.6M | $584.4M | ||
| Q1 24 | $20.0M | $401.2M |
总资产HHSRXRX
| Q4 25 | $91.8M | $1.5B | ||
| Q3 25 | $92.7M | $1.4B | ||
| Q2 25 | $95.0M | $1.3B | ||
| Q1 25 | $100.6M | $1.3B | ||
| Q4 24 | $101.8M | $1.4B | ||
| Q3 24 | $108.1M | $726.5M | ||
| Q2 24 | $109.7M | $775.9M | ||
| Q1 24 | $113.4M | $557.8M |
负债/权益比HHSRXRX
| Q4 25 | — | 0.01× | ||
| Q3 25 | — | 0.01× | ||
| Q2 25 | — | 0.02× | ||
| Q1 25 | — | 0.02× | ||
| Q4 24 | — | 0.02× | ||
| Q3 24 | — | 0.04× | ||
| Q2 24 | — | 0.04× | ||
| Q1 24 | — | — |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $737.0K | $-46.1M |
| 自由现金流经营现金流 - 资本支出 | $-686.0K | $-47.3M |
| 自由现金流率自由现金流/营收 | -1.7% | -133.1% |
| 资本支出强度资本支出/营收 | 3.6% | 3.5% |
| 现金转化率经营现金流/净利润 | 0.33× | — |
| 过去12个月自由现金流最近4个季度 | $-4.5M | $-378.3M |
8季度趋势，按日历期对齐
经营现金流HHSRXRX
| Q4 25 | $737.0K | $-46.1M | ||
| Q3 25 | $3.2M | $-117.4M | ||
| Q2 25 | $-4.8M | $-76.4M | ||
| Q1 25 | $-818.0K | $-132.0M | ||
| Q4 24 | $4.0M | $-115.4M | ||
| Q3 24 | $-2.9M | $-59.2M | ||
| Q2 24 | $1.6M | $-82.2M | ||
| Q1 24 | $-5.7M | $-102.3M |
自由现金流HHSRXRX
| Q4 25 | $-686.0K | $-47.3M | ||
| Q3 25 | $2.2M | $-117.6M | ||
| Q2 25 | $-5.1M | $-79.6M | ||
| Q1 25 | $-923.0K | $-133.8M | ||
| Q4 24 | $3.4M | $-116.7M | ||
| Q3 24 | $-4.9M | $-63.8M | ||
| Q2 24 | $926.0K | $-83.4M | ||
| Q1 24 | $-6.2M | $-109.0M |
自由现金流率HHSRXRX
| Q4 25 | -1.7% | -133.1% | ||
| Q3 25 | 5.5% | -2272.5% | ||
| Q2 25 | -13.1% | -413.9% | ||
| Q1 25 | -2.2% | -907.4% | ||
| Q4 24 | 7.3% | -2567.7% | ||
| Q3 24 | -10.2% | -244.6% | ||
| Q2 24 | 2.1% | -578.5% | ||
| Q1 24 | -13.7% | -789.9% |
资本支出强度HHSRXRX
| Q4 25 | 3.6% | 3.5% | ||
| Q3 25 | 2.5% | 4.7% | ||
| Q2 25 | 0.6% | 16.4% | ||
| Q1 25 | 0.3% | 12.4% | ||
| Q4 24 | 1.3% | 28.6% | ||
| Q3 24 | 4.0% | 17.5% | ||
| Q2 24 | 1.5% | 8.2% | ||
| Q1 24 | 1.2% | 48.2% |
现金转化率HHSRXRX
| Q4 25 | 0.33× | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | -20.76× | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
HHS
| Fulfillment And Logistics Services | $17.3M | 43% |
| Customer Care | $13.7M | 34% |
| Other | $8.9M | 22% |
RXRX
暂无分部数据
